11.07.25 -- New Podcast Episodes: Blocking Neuroinflammation, BoB In South Florida, Sanofi's Genomic Medicine Vision

Check out the latest episodes from Better Biopharma, Cell & Gene: The Podcast, and Business of Biotech. As a member of the Life Science Connect community, you have access to content beyond our weekly newsletters, including our podcast series.

In this episode, host Tyler Menichiello is joined by OS Therapies’ CEO, Paul Romness, and chief medical and scientific officer, Robert Petit, Ph.D. The three discuss the development and manufacturing of the company’s lead asset, OST-HER2, a Listeria-based immunotherapy for osteosarcoma.

Host Tyler Menichiello is joined by MindImmune's president and CEO, Stevin Zorn, Ph.D. They discuss the development of the company's lead candidate, MITI-101, a monoclonal antibody designed to prevent peripheral immune cells from entering the brain and driving neuroinflammation linked to Alzheimer's disease.

Rob Abbott, CEO of ISPOR, explains how startup and early-stage clinical drug development companies benefit from conducting health economics and outcomes research (HEOR), and not just with patients and commercial payers.

The Business of Biotech is on location in Miami. For the first episode in this four-part series on the biotech scene in South Florida, Raquel Cabo, Founder and President of the Miami Biotech Collective, talks about her experiences as a member of the founding team at Ovid Therapeutics, why South Florida needed an organization to connect regional drug developers, and more.

In this episode -- part two in a four-part series recorded in-person at Catalyst Pharmaceuticals' Miami headquarters -- we're speaking with Daniel Teper, an entrepreneur and most recently, founder and CEO at NAYA Therapeutics.

Anthony Japour, M.D., CEO at iTolerance, talks about his work as a physician treating infectious diseases, his CEO role in diagnostics at the height of the COVID-19 pandemic, what he learned working as a medical director at a large CRO, and iTolerance's work toward a cure for Type 1 diabetes that doesn't require chronic immunosuppression.

On this episode — the last of our four-part series focused on South Florida — we catch up with Rich Daly, CEO at Catalyst Pharmaceuticals, a member of Life Science Leader's editorial advisory board and Miami-based location host for our in-person series. 

On this episode of Cell & Gene: The Podcast, Host Erin Harris talks to Ernexa Therapeutics' President and CEO, Sanjeev Luther, about how the company is advancing cell therapy innovation for cancer and autoimmune disease through engineered induced pluripotent stem cell-derived mesenchymal stem cells (iMSCs).

Michael Quigley, Ph.D., Chief Scientific Officer and Global Head of Research at Sanofi talks to Host Erin Harris about the establishment of Sanofi’s dedicated Genomic Medicine Unit (GMU). Dr. Quigley emphasizes in vivo delivery and process optimization to improve patient experience, scalability, and global access.

Host Erin Harris is joined by Thorsten Gorba, Ph.D., of Aspen Neuroscience to explore how the company is advancing the field of cell therapy manufacturing.

Brian Culley, CEO of Lineage Cell Therapeutics, discusses advancing cell therapy beyond oncology and into transformative treatments for conditions such as spinal cord injury and blindness.